CALCITRIOL (calcitriol) by Fosun Pharma is clinical pharmacology man's natural supply of vitamin d depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin d 3 (cholecalciferol). Approved for the management of secondary hyperparathyroidism, resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis, the management of hypocalcemia and 4 more indications. First approved in 2019.
Drug data last refreshed 20h ago
CLINICAL PHARMACOLOGY Man's natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin D 3 (cholecalciferol). Vitamin D 3 must be metabolically activated in the liver and the kidney before it is fully…
Worked on CALCITRIOL at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Vitamin D3 Analog
Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis
Oral Calcitriol With Ketoconazole in CRPC
Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients